<DOC>
	<DOCNO>NCT00847600</DOCNO>
	<brief_summary>Pregnenolone ( PREG ) neurosteroid , display multiple effect central nervous system , may beneficial treatment patient schizophrenia . Our recent 8-week , randomize , double-blind trial among patient chronic schizophrenia schizoaffective disorder , PREG versus placebo DHEA add conventional atypical antipsychotic yield encouraging result low-dose PREG ( 30 mg/day ; ClinicalTrials.gov identifier NCT00140192 ; Ritsner et al. , press ) . The goal present study evaluate potential role PREG 's augmentation compare placebo treatment young patient newly diagnose schizophrenia schizophreniform schizoaffective disorder . In 8-week , randomize , double-blind placebo-controlled trial PREG ( 50 mg/day ) placebo capsule add stable ongoing antipsychotic treatment 60 patient recent-onset schizophrenia schizophreniform schizoaffective disorder . Participants assess baseline 2 , 4 , 6 8 week treatment . A battery research instrument use assessment psychopathology , cognitive function , side effect , general functioning quality life . In addition blood PREG level monitor baseline study . The study power detect moderate between-group effect persistent positive , negative cognitive symptom .</brief_summary>
	<brief_title>Pregnenolone Augmentation Treatment Patients With Recent-Onset Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>1 . 1840 year age , ethnic group , either sex . 2 . DSMIV criterion schizophrenia , schizophreniform schizoaffective disorder ( 36 ) . 3 . Duration illness le 5 year since onset first psychotic episode . 4 . Subjects enter study must score least 4 Clinical Global Impression Scale . 5 . At least two week ongoing treatment current antipsychotic agent pretreatment stabilization period . 6 . Stable symptom throughout 2week pretreatment stabilization period . Clinical stability define two consecutive weekly CGI rating change score , 20 % change PANSS total score . 7 . No change anticholinergic , benzodiazepine , mood stabilizer medication pretreatment stabilization period . 8 . No anticipated need alter medication ( antipsychotic , anticholinergic , benzodiazepine , mood stabilizer ) 8week duration study . 9 . Ability participate fully informed consent process , legal guardian able participate inform consent process . 1 . Evidence serious neurologic endocrine disorder , example severe head trauma , seizure disorder , dementia , Cushings disease , thyroid disorder , mental retardation , alcohol drug abuse , substance dependence ( nicotine dependence ) , present symptom likely substanceinduced , judge study physician . 2 . Unstable medical illness neurologic illness ( seizure , CVA ) ; history prostate , breast , uterine , ovarian cancer . 3 . Pregnant woman , use oral contraceptive hormonal supplementation estrogen . 4 . Current active suicidal and/or homicidal ideation , intent , plan . 5 . Known allergy study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Neurosteroids</keyword>
	<keyword>Pregnenolone</keyword>
	<keyword>Augmentation</keyword>
</DOC>